Table 2.
Values applied for vaccine-specific inputs for base-case and sensitivity analyses and data sources
| Age group (years) | Base value (%) | Rangea (bounds-%) | Data sources | |||
|---|---|---|---|---|---|---|
| Lower | Upper | Base value | Range | |||
| Initial HZ efficacy: RZV (one dose) | 50–69 | 90.00 | 58.90 | 98.90 | [21] | [21] |
| ≥ 70 | 69.50 | 24.90 | 89.10 | [21] | [21] | |
| Initial HZ efficacy: RZV (two doses) | 50–69 | 98.40 | 95.00 | 100.00 | [21] | [21] |
| ≥ 70 | 97.84 | 94.10 | 100.00 | [21] | [21] | |
| Initial HZ efficacy: VVL | 50–59 | 69.80 | 54.10 | 80.60 | [29] | [29] |
| 60–69 | 63.89 | 56.00 | 71.00 | [28, 46] | [21, 46] | |
| 70–79 | 40.85 | 28.00 | 52.00 | [28, 46] | [21, 46] | |
| ≥ 80 | 18.25 | 0.00 | 48.00 | [28, 46] | [21, 46] | |
| Initial PHN efficacy: RZV (one dose) | 50–69 | 90.00 | – | – | [21] | N/A |
| ≥ 70 | 69.50 | – | – | [21] | N/A | |
| Initial PHN efficacy: RZV (two doses) | 50–59 | 98.40 | – | – | [21] | N/A |
| ≥ 70 | 97.84 | – | – | [21] | N/A | |
| Initial PHN efficacy: VVL | 50–59 | 69.80 | – | – | Assumedb | N/A |
| 60–69 | 65.69 | – | – | [28, 46] | N/A | |
| 70–79 | 73.38 | – | – | [28, 46] | N/A | |
| ≥ 80 | 39.51 | – | – | [28, 46] | N/A | |
| Annual waning of efficacy: RZV (one dose) | All for years 1–4 | 5.40 | 1.00 | 7.40 | Assumedc | [21] |
| All for years ≥ 5 | 5.10 | 3.60 | 6.90 | Assumedc | [21] | |
| Annual waning of efficacy: RZV (two doses) | 50–69 for years 1–4 | 1.00 | 0.00 | 2.60 | [21] | [21] |
| 50–69 for years ≥ 5 | 2.30 | 0.70 | 4.60 | [21] | [21] | |
| ≥ 70 | 3.60 | 1.40 | 6.60 | [21] | [21] | |
| Annual waning of efficacy: VVL | All for years 1–4 | 5.40 | 4.50 | 6.40 | [21] | [21] |
| All for years ≥ 5 | 5.10 | 4.10 | 6.00 | [21] | [21] | |
| Coverage | All | 40.00 | 20.00 | 60.00 | Assumedd | Assumedd |
| Second-dose compliance for RZV | All | 95.00 | 70.00 | 100.00 | [31, 32]e | Assumede |
RZV Recombinant Zoster Vaccine, VVL Varicella Vaccine Live, HZ Herpes Zoster, PHN Postherpetic Neuralgia, N/A Not Applicable
a–, Not varied in the sensitivity analysis
bAssumed to be the same as the initial efficacy in preventing HZ
cAssumed to be the same as the waning rate of VVL efficacy
dAssumed to be the same as that in a recently introduced vaccine for elderly, pneumococcal polysaccharide vaccine-23 [34]. Assumed to be ± 20% of base case for the upper/lower bound, respectively
eAs there were no available data in Japan, second-dose compliance in this analysis was assumed to be the same as that obtained from two clinical trials [31, 32]. Assumed to be 70 and 100% for the lower/upper bound, respectively